Literature DB >> 23912191

Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases.

Christopher King1, Steven D Nathan.   

Abstract

PURPOSE OF REVIEW: The interstitial lung diseases (ILDs) frequently result in considerable disability and reduced survival in affected patients. Unfortunately, they are often poorly responsive to available therapies. Comorbidities, both pulmonary and nonpulmonary, frequently accompany ILDs and contribute to adverse outcomes. RECENT
FINDINGS: Multiple comorbidities, including gastroesophageal reflux disease, venous thromboembolism, coronary artery disease, sleep-disordered breathing, depression, emphysema, pulmonary hypertension, and lung cancer contribute to the morbidity and mortality of fibrotic lung disease.
SUMMARY: The identification and treatment of comorbidities may improve morbidity and potentially impact mortality in patients with ILD. A high index of suspicion and an awareness of the spectrum of comorbidities are important in optimizing outcomes in this group of patients.

Entities:  

Mesh:

Year:  2013        PMID: 23912191     DOI: 10.1097/MCP.0b013e328363f460

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  14 in total

1.  Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis.

Authors:  Charalampos Mermigkis; Izolde Bouloukaki; Katerina Antoniou; Georgios Papadogiannis; Ioannis Giannarakis; Georgios Varouchakis; Nikolaos Siafakas; Sophia E Schiza
Journal:  Sleep Breath       Date:  2014-07-16       Impact factor: 2.816

2.  Two sides of a coin: the dual roles of chitinase 3-like 1 in idiopathic pulmonary fibrosis.

Authors:  Christina S Turn; Narasaiah Kolliputi
Journal:  Lung       Date:  2014-10-01       Impact factor: 2.584

Review 3.  Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?

Authors:  Steven D Nathan; Christopher S King
Journal:  Drug Des Devel Ther       Date:  2014-07-02       Impact factor: 4.162

Review 4.  Diagnosis and management of interstitial lung disease.

Authors:  Keith C Meyer
Journal:  Transl Respir Med       Date:  2014-02-13

5.  Quality of life assessment in interstitial lung diseases:a comparison of the disease-specific K-BILD with the generic EQ-5D-5L.

Authors:  Boglárka Lilla Szentes; Michael Kreuter; Thomas Bahmer; Surinder S Birring; Martin Claussen; Julia Waelscher; Reiner Leidl; Larissa Schwarzkopf
Journal:  Respir Res       Date:  2018-05-25

6.  Six-minute walk distance and survival time in patients with idiopathic pulmonary fibrosis in Brazil.

Authors:  Eliane Viana Mancuzo; Maria Raquel Soares; Carlos Alberto de Castro Pereira
Journal:  J Bras Pneumol       Date:  2018 Jul-Aug       Impact factor: 2.624

7.  Interstitial lung diseases in the hospitalized patient.

Authors:  Supparerk Disayabutr; Carolyn S Calfee; Harold R Collard; Paul J Wolters
Journal:  BMC Med       Date:  2015-09-25       Impact factor: 8.775

Review 8.  Role of pirfenidone in the management of pulmonary fibrosis.

Authors:  Keith C Meyer; Catherine A Decker
Journal:  Ther Clin Risk Manag       Date:  2017-04-03       Impact factor: 2.423

9.  Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis.

Authors:  Larissa Schwarzkopf; Sabine Witt; Julia Waelscher; Markus Polke; Michael Kreuter
Journal:  Respir Res       Date:  2018-04-25

Review 10.  Therapeutic Approach to Adult Fibrotic Lung Diseases.

Authors:  Ayodeji Adegunsoye; Mary E Strek
Journal:  Chest       Date:  2016-08-10       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.